Interventions for cisplatin-induced hearing loss in children and adolescents with cancer

David R. Freyer, Penelope Brock, Kristin Knight, Gregory Reaman, Sandra Cabral, Paula D. Robinson, Lillian Sung

Research output: Contribution to journalReview article

Abstract

The identification of preventive interventions that are safe and effective for cisplatin-induced ototoxicity is important, especially in children because hearing loss can impair speech-language acquisition development. Previous randomised trials assessed systemic drugs such as amifostine, sodium diethyldithiocarbamate or disulfiram, and sodium thiosulfate. Amifostine, sodium diethyldithiocarbamate, and disulfiram did not show hearing preservation. Paediatric trials assessing sodium thiosulfate showed efficacy in terms of hearing protection. The SIOPEL 6 trial consisted solely of patients with localised hepatoblastoma and no effects on survival were shown. In the ACCL0431 trial, which included heterogeneous patients, a post-hoc analysis showed significantly worse overall survival among patients who had disseminated disease receiving sodium thiosulfate than among controls, but not among those with localised disease. Intratympanically administered drugs have mainly been assessed in adults and include N-acetylcysteine and dexamethasone. Inconsistent effects of these drugs were identified but these studies were limited by design, small sample size, and statistical approach. Future studies of systemic drugs will need to consider the measurement of disease outcomes through study design and sample size, and ototoxicity endpoints should be harmonised to enhance comparability between trials.

Original languageEnglish (US)
Pages (from-to)578-584
Number of pages7
JournalThe Lancet Child and Adolescent Health
Volume3
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Hearing Loss
Cisplatin
Amifostine
Ditiocarb
Disulfiram
Pharmaceutical Preparations
Sample Size
Hearing
Neoplasms
Hepatoblastoma
Language Development
Survival
Acetylcysteine
Dexamethasone
Outcome Assessment (Health Care)
Pediatrics
sodium thiosulfate

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology

Cite this

Interventions for cisplatin-induced hearing loss in children and adolescents with cancer. / Freyer, David R.; Brock, Penelope; Knight, Kristin; Reaman, Gregory; Cabral, Sandra; Robinson, Paula D.; Sung, Lillian.

In: The Lancet Child and Adolescent Health, Vol. 3, No. 8, 01.08.2019, p. 578-584.

Research output: Contribution to journalReview article

Freyer, David R. ; Brock, Penelope ; Knight, Kristin ; Reaman, Gregory ; Cabral, Sandra ; Robinson, Paula D. ; Sung, Lillian. / Interventions for cisplatin-induced hearing loss in children and adolescents with cancer. In: The Lancet Child and Adolescent Health. 2019 ; Vol. 3, No. 8. pp. 578-584.
@article{8c312d4a6e4443f5a5c5161c632838dd,
title = "Interventions for cisplatin-induced hearing loss in children and adolescents with cancer",
abstract = "The identification of preventive interventions that are safe and effective for cisplatin-induced ototoxicity is important, especially in children because hearing loss can impair speech-language acquisition development. Previous randomised trials assessed systemic drugs such as amifostine, sodium diethyldithiocarbamate or disulfiram, and sodium thiosulfate. Amifostine, sodium diethyldithiocarbamate, and disulfiram did not show hearing preservation. Paediatric trials assessing sodium thiosulfate showed efficacy in terms of hearing protection. The SIOPEL 6 trial consisted solely of patients with localised hepatoblastoma and no effects on survival were shown. In the ACCL0431 trial, which included heterogeneous patients, a post-hoc analysis showed significantly worse overall survival among patients who had disseminated disease receiving sodium thiosulfate than among controls, but not among those with localised disease. Intratympanically administered drugs have mainly been assessed in adults and include N-acetylcysteine and dexamethasone. Inconsistent effects of these drugs were identified but these studies were limited by design, small sample size, and statistical approach. Future studies of systemic drugs will need to consider the measurement of disease outcomes through study design and sample size, and ototoxicity endpoints should be harmonised to enhance comparability between trials.",
author = "Freyer, {David R.} and Penelope Brock and Kristin Knight and Gregory Reaman and Sandra Cabral and Robinson, {Paula D.} and Lillian Sung",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/S2352-4642(19)30115-4",
language = "English (US)",
volume = "3",
pages = "578--584",
journal = "The Lancet Child and Adolescent Health",
issn = "2352-4642",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - Interventions for cisplatin-induced hearing loss in children and adolescents with cancer

AU - Freyer, David R.

AU - Brock, Penelope

AU - Knight, Kristin

AU - Reaman, Gregory

AU - Cabral, Sandra

AU - Robinson, Paula D.

AU - Sung, Lillian

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The identification of preventive interventions that are safe and effective for cisplatin-induced ototoxicity is important, especially in children because hearing loss can impair speech-language acquisition development. Previous randomised trials assessed systemic drugs such as amifostine, sodium diethyldithiocarbamate or disulfiram, and sodium thiosulfate. Amifostine, sodium diethyldithiocarbamate, and disulfiram did not show hearing preservation. Paediatric trials assessing sodium thiosulfate showed efficacy in terms of hearing protection. The SIOPEL 6 trial consisted solely of patients with localised hepatoblastoma and no effects on survival were shown. In the ACCL0431 trial, which included heterogeneous patients, a post-hoc analysis showed significantly worse overall survival among patients who had disseminated disease receiving sodium thiosulfate than among controls, but not among those with localised disease. Intratympanically administered drugs have mainly been assessed in adults and include N-acetylcysteine and dexamethasone. Inconsistent effects of these drugs were identified but these studies were limited by design, small sample size, and statistical approach. Future studies of systemic drugs will need to consider the measurement of disease outcomes through study design and sample size, and ototoxicity endpoints should be harmonised to enhance comparability between trials.

AB - The identification of preventive interventions that are safe and effective for cisplatin-induced ototoxicity is important, especially in children because hearing loss can impair speech-language acquisition development. Previous randomised trials assessed systemic drugs such as amifostine, sodium diethyldithiocarbamate or disulfiram, and sodium thiosulfate. Amifostine, sodium diethyldithiocarbamate, and disulfiram did not show hearing preservation. Paediatric trials assessing sodium thiosulfate showed efficacy in terms of hearing protection. The SIOPEL 6 trial consisted solely of patients with localised hepatoblastoma and no effects on survival were shown. In the ACCL0431 trial, which included heterogeneous patients, a post-hoc analysis showed significantly worse overall survival among patients who had disseminated disease receiving sodium thiosulfate than among controls, but not among those with localised disease. Intratympanically administered drugs have mainly been assessed in adults and include N-acetylcysteine and dexamethasone. Inconsistent effects of these drugs were identified but these studies were limited by design, small sample size, and statistical approach. Future studies of systemic drugs will need to consider the measurement of disease outcomes through study design and sample size, and ototoxicity endpoints should be harmonised to enhance comparability between trials.

UR - http://www.scopus.com/inward/record.url?scp=85068521862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068521862&partnerID=8YFLogxK

U2 - 10.1016/S2352-4642(19)30115-4

DO - 10.1016/S2352-4642(19)30115-4

M3 - Review article

VL - 3

SP - 578

EP - 584

JO - The Lancet Child and Adolescent Health

JF - The Lancet Child and Adolescent Health

SN - 2352-4642

IS - 8

ER -